Marimastat: Phase III

BBG's 369-patient placebo-controlled Phase III monotherapy study missed its primary end point of improved survival in individuals with inoperable gastric cancer. Patients received either 10 mg of marimastat or placebo orally twice per day. At the pre-defined clinical end point (when 85 percent of patients in either of the study groups died), 22.7 percent of marimastat-treated patients were alive compared with 14.1 percent of patients receiving placebo (p=0.084). ...